ArticleCommunications biology2025
Trio and CRMP2 regulate axon branching and Semaphorin3A signaling.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Semaphorins and Their Role in Neuropathic Pain.Life (Basel, Switzerland) · 2026Review
- A novel m7G RNA methylation-related signature associated with MAPK signaling pathways in acute ischemic stroke.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Trio is a neuronally expressed, Rac1- and RhoA-activating RhoGEF, that is required for neurodevelopment. Mutations affecting the Rac1-activating GEF domain of Trio are associated with profound neurodevelopmental delay and Trio knock-out is embryonic lethal. Although there are studies showing a role for Trio in axon patterning, our understanding of the mechanistic underpinnings of Trio function is incomplete. We have now taken an unbiased approach to identifying the interactome of Trio in embryonic axonal compartments. Using immunoprecipitation-mass spectrometry, we identified the Collapsin Response Mediator Protein 2 (CRMP2) as a robust association partner of growth cone-localized Trio. Like Trio, CRMP2 has a well-known role in shaping the cytoskeleton, particularly during axon patterning. In the current study, we demonstrate Trio preferentially interacts with phosphorylated CRMP2 (pCRMP2) and is recruited by pCRMP2 to limit filopodial motility and axon branching. By introducing a GEF1-ablating disease-related mutation, we further demonstrate that Trio-GEF1 signaling is required for pCRMP2-mediated axon branch suppression. Finally, we show that Semaphorin3A invokes pCRMP2-Trio signaling to limit axon branching in vitro, revealing a developmental role for pCRMP2-Trio signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.